Back mutation

Author:Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 16.01.2022

Dieser Artikel auf Deutsch

Synonym(s)

reversion

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

Reverse mutation is understood to be a mutation that phenotypically and genotypically converts a mutated genotype back to the wild type (to the original genetic type), i.e. normalizes it, by exactly restoring the original nucleotide sequence. In the case of focally back-mutated skin, a normal skin appearance is again seen in a pathological environment, at these sites.

Back mutations can be distinguished from compensating mutations by crossing "back mutant × wild type". If a back mutation is present, the entire progeny corresponds to the wild type, whereas if a compensating mutation is present, the mutants reappear in the progeny due to recombination.

Note(s)This section has been translated automatically.

An organism, or as in the case of reverse mosaics, a cell clone, that shows the original phenotype (usually of the wild type) due to a reverse mutation is called a reverse mutant or revertant.

The phenomenon of back mutaion has been demonstrated, for example, in epidermolysis bullosa. It is likely that such back mutant areas also exist in other autosomal recessive genodermatoses, for example in xeroderma pigmentosum, but have so far remained unnoticed.The phenomenon represents, so to speak, a kind of natural gene therapy .

Furthermore, reversion mutations play a role, for example, in the development of therapy resistance to chemotherapeutic agents of breast and ovarian carcinomas as well as in pancreatic and prostate carcinomas. Tumors in these patients tend to lose both copies of the wild-type BRCA gene, making them particularly sensitive to platinum drugs and poly(ADP-ribose) polymerase inhibitors (PARPi), the therapies of choice in these diseases.

Pharmacological inhibition of DNA end-joining repair pathways improves drug treatment outcomes by preventing the acquisition of reversion mutations in BRCA genes, for example (Tobalina L et al. 2021).

LiteratureThis section has been translated automatically.

  1. Cisneros L et al. (2017) Ancient genes establish stress-induced mutation as a hallmark of cancer. PLoS One 12:e0176258.
  2. Edgington MPet al (2019) Modeling the mutation and reversal of engineered underdominance gene drives. J Theor Biol 479:14-21.
  3. Tobalina L et al (2021) A meta-analysis of reversion mutations in BRCA genes identifies signatures of DNA end-joining repair mechanisms driving therapy resistance. Ann Oncol 32:103-112.
  4. Tomala K et al (2019) Limits to compensatory mutations: insights from temperature-sensitive alleles. Mol Biol Evol 36:1874-1883.

Authors

Last updated on: 16.01.2022